Dr. Thomas D Puleo, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5 Main St Ste 1, Lyme, NH 03768 Phone: 401-261-4875 |
News Archive
Are people who think creatively different from those who tend to think in a more methodical fashion?
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
A new study by researchers in the U.S. further supports the hypothesis that the unregulated release of inflammatory cytokines is responsible for the local and systemic inflammation that is associated with multi-organ damage and death in severe COVID-19.
"Johnson & Johnson [J&J] said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis [TB] in more than four decades," the Associated Press reports, adding, "The experimental drug, called bedaquiline, also would be the first medicine specifically for treating multi-drug resistant tuberculosis."
Scientists at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center have received approval for a first-of-its kind study on the effect high dose vitamin C has on non-Hodgkin lymphoma patients.
› Verified 6 days ago